CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility
CMC biologics announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site. The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.
The multi-purpose, single-use facility will allow for early-phase clinical manufacture of a range of biopharmaceuticals, including monoclonal antibodies and other mammalian cell culture-based recombinant proteins. CMC Biologics has partnered with Hyclone to supply the new disposable facility with processing equipment, including a 100L and two 500L single-use bioreactors (SUBs) and disposable mixers.
"Disposable technology offers the advantages of increased flexibility and efficiency, decreased cross-contamination risks, and elimination of cleaning, sterilization and other change-over procedures typically associated with traditional steel tank facilities, while providing the same performance," said Andy Walker, Senior Director of Manufacturing. "Consequently, it provides a cost-effective strategy for reducing the speed to market for many biologics."
For other products where use of disposables is not feasible, CMC Biologics continues to offer its stainless-steel clinical and commercial cGMP manufacturing facility. They are currently increasing capacity with the addition of a second 3000L bioreactor train, identical to the existing line. Recent client demand has prompted initial steps in the plan toward build-out of a pre-existing structure anticipated to house two 5000L commercial-ready manufacturing lines. CMC Biologics has also increased headcount by more than 30% at its Seattle site to support the expansion.
Other news from the department manufacturing
These products might interest you
Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance
Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels
Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures
Flexcell Systems by Dunn
Flexcell Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 4000 research publications
Brooks Instrument SLA Biotech-Serie by Brooks Instrument
Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications
The SLA Biotech series has been developed specifically for the requirements in bioprocesses
SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument
SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)
Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
